



## **Integrum invites to presentation of Q3 2025/26 results**

**Mölnadal, Sweden – March 3, 2026 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) will host a live webcast presentation of its third quarter 2025/26 results on Thursday, March 5, 2026, at 10:00 CET.**

CEO Martin Hillsten will present the report together with CFO Louise Wåhlin. Participants will have the opportunity to ask questions during the webcast.

The webcast can be accessed at:

<https://www.finwire.tv/webcast/integrum/q3-2025/>

The report will be available at:

<https://integrum.se/investor-relations/financial-reports-calendar/>

### **For more information, please contact:**

Louise Wåhlin, CFO

Phone: + 46 (0) 734 63 73 03

E-mail: [louise.wahlin@integrum.se](mailto:louise.wahlin@integrum.se)

### **Certified Adviser**

The Company's Certified Adviser is DNB Carnegie Investment Bank AB.

### **About Integrum**

Integrum AB is a publicly traded company (INTEG B: Nasdaq First North Growth Market) based outside of Gothenburg, Sweden, with a U.S. subsidiary in San Francisco. Since 1990, its OPRA™ Implant System has helped improve the quality of life for hundreds of people who are amputees by directly attaching a prosthesis to the bone and musculoskeletal system, therefore avoiding the need for a socket. Based on osseointegration, the bone-anchored implant system offers a range of benefits, including improved mobility and function, enhanced comfort, reduced pressure, a stable attachment and more. The OPRA™ Implant System was approved by the U.S. Food and Drug Administration (FDA) in 2020 and is the only FDA-approved bone-anchored implant system specifically designed for use in amputees available in the U.S. Today, Integrum continues to perform research and develop custom-made medical device solutions in close collaboration with scientists and clinicians. To learn more, please visit <https://integrum.se/>.